EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid and Durable Skin Pain Relief with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Christopher Bunick, Peter Lio, Mona Shahriari, Diego Ruiz Dasilva, Ayman Grada, Brian Calimlim, David Prefontaine, Chao Li, Jianzhong Zhang, Vipul Jain, Pedro Mendes-Bastos, Eric Simpson

SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s741

DOI: 10.25251/mwffsw72 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von Christopher Bunick und 11 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Itch, skin pain, and eczematous lesions are features of atopic dermatitis (AD). Skin pain is increasingly recognized as both a common and burdensome symptom of AD, reported by 61% of patients, that can impair daily activities, sleep, and mental health.Upadacitinib (UPA) is an oral selective Janus kinase 1 inhibitor approved for the treatment of AD and multiple other conditions. In this study, we assessed the efficacy of UPA in reducing skin pain in adults and adolescents with moderate-to-severe AD. This analysis evaluated integrated data from patients with moderate-to-severe AD treated with UPA monotherapy in two studies: Measure Up 1 and Measure Up 2. Patients were randomized to receive UPA 15mg (UPA15), UPA 30mg (UPA30), or placebo for 16 weeks in the double-blind, placebo-controlled period. At week 16, patients randomized to UPA groups continued treatment, and placebo groups were re-randomized to UPA15 or UPA30 for the double-blind, long-term extension period. Skin pain (SP) was assessed using a validated patient-reported outcome (PRO) measure, the Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain numerical rating scale (NRS); the optimal outcome was defined as an SP-NRS score of 0 or 1 (SP-NRS 0/1), indicating no/minimal skin pain. Among patients who achieved SP-NRS 0/1 at week 16, long-term maintenance of response was evaluated through week 140. Patient-reported impacts of achieving SP-NRS 0/1 on sleep, daily activities, and quality of life (QOL) outcomes were assessed. Response rates were based on non-responder imputation (NRI) through week 16 and observed cases (OC) through week 140. At baseline, 85% of patients reported skin pain. Compared with placebo (n=531), patients treated with UPA15 (n=524) and UPA30 (n=543) achieved higher rates of SP-NRS 0/1 as early as day 2 (the day after treatment initiation), with response rates increasing through day 28 (UPA15: 43.7%, UPA30: 57.6%; both p

Zitieren

APA

Bunick, C., Lio, P., Shahriari, M., Dasilva, D. R., Grada, A., Calimlim, B., Prefontaine, D., Li, C., Zhang, J., Jain, V., Mendes-Bastos, P., & Simpson, E. (2026). Rapid and Durable Skin Pain Relief with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 10(2), s741. https://doi.org/10.25251/mwffsw72

Vancouver

Bunick C, Lio P, Shahriari M, Dasilva DR, Grada A, Calimlim B, et al. Rapid and Durable Skin Pain Relief with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s741. doi:10.25251/mwffsw72

BibTeX
@article{Bunick2026,
  author = {Bunick, Christopher and Lio, Peter and Shahriari, Mona and Dasilva, Diego Ruiz and Grada, Ayman and Calimlim, Brian and Prefontaine, David and Li, Chao and Zhang, Jianzhong and Jain, Vipul and Mendes-Bastos, Pedro and Simpson, Eric},
  title = {Rapid and Durable Skin Pain Relief with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {2},
  pages = {s741},
  doi = {10.25251/mwffsw72}
}
Kostenlos starten →